Enzyme foams morer active and stable
Researchers at the Karlsruhe Institute of Technology (KIT) have transformed enzymes into a new form: as foams, the biocatalysts prove to be extremely stable and active.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1247 entries already.
Entries by Thomas Gabrielczyk
Bavarian Nordic A/S bags US$120m for smallpox vaccine
/in News/by Thomas GabrielczykBavarian Nordic A/S will get US$120m from a contract for the manufacturing of smallpox and mpox vaccine from the US government.
Neuraxpharm pays US$650m for MS drug commercialisation
/in News/by Thomas GabrielczykTG Therapeutics will receive US$140m upfront from German Neuraxpharm for Ex-US commercialisation rights of its deglycosylated anti-CD20 antibody ublituximab-xiiy.
PureTech Health gets US$11.4m to advance LYT-300
/in News/by Thomas GabrielczykLSE-listed PureTech Health plc hat been granted p to US$11.4m from U.S. Department of Defense to advance LYT-300 to treat Fragile X-associated tremor/ataxia syndrome.
Mithra Pharmaceuticals SA in 17m licencing deal
/in News/by Thomas GabrielczykMithra and Searchlight Pharma have inked a licensing deal for Donesta commercialisation in Canada.
Bacterial-fungal consortium denitrifies wastewater by 100%
/in News/by Thomas GabrielczykA German-Chinese reasearch consortium has identified a highly active denitrifying microbial consortium that denitrifies wastewater by almost 100%.
NK cell therapy company NK:IO raises seed money
/in News/by Thomas GabrielczykBritish NK cell therapy specialist NK:IO Ltd has added a £1.2m seed investment led by Cancer Research Horizons, bringing total seed funding to £5.1m.
Alnylam in US$2.8bn biobucks deal with Roche
/in News/by Thomas GabrielczyksiRNA specialist Alnylam Pharmaceuticals Roche has received US$310m upfront from Swiss Roche AG for the ex-US commercialisation rights of zilebesiran, an new antihypertensive. T
Resistance blocker of immune checkpoint inhibitors gets patented
/in News/by Thomas GabrielczykThe EPO has granted a patent to Domain Therapeutics Phase I candidate DT-9081 designed to reverse PGE2-mediated immunosuppression used by tumours to bypass the immune system.
Lilly presents impressing results for Alzheimer’s drug donanemab
/in News/by Thomas GabrielczykEli Lilly’s Alzheimer’s drug donanemab has speedy removed amyloid plaques in a pivotal Phase III trail halting disease progression for one year in half of patients.